Octagam 5% human IV immunoglobulin: Phase II/III started

On Dec. 18, 2013, Octapharma began the European Phase II/III GAM-27 trial to compare 0.6 g/kg IV Octagam 5% vs. first-line therapy with Copaxone glatiramer acetate or beta interferon for about 24 months in about 216 patients with early relapsing MS. Patients will be stratified into either predicted responders or predicted non-responders according to the Heidelberg Assay Panel. ...